Trial intelligence / Profile preview

Zanzalintinib in Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma

NCT07714551Phase 2

Key facts

Status: Not yet recruiting
Start: Jan 2027
Primary completion: Jan 2031
Countries: 1
Sponsor: Dana-Farber Cancer Institute

Drugs: zanzalintinib
Conditions: pheochromocytomaParaganglioma (PGL)

Overview

Phase 2, open-label, single-arm trial of zanzalintinib in pheochromocytoma and Paraganglioma (PGL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate up to 16 months. Planned start Jan 2027; status: not yet recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Zanzalintinib
Participants receive zanzalintinib 60 mg orally once daily.

Who it enrols

Adults with unresectable and progressive metastatic pheochromocytoma or paraganglioma, measurable disease, ECOG <= 2, adequate organ function. Excludes patients with recent prior therapies, uncontrolled cardiovascular or gastrointestinal disorders, active infections, or moderate/severe hepatic impairment.

Endpoints

Primary

Objective Response Rateup to 16 months

Secondary

Progression-Free Survivalup to 16 months
Overall Survivalup to 16 months
Global Adverse Event Rateup to 16 months
Blood Pressure Control Rateup to 16 months
Biochemical Response Rateup to 16 months
Functional Assessment of Cancer Therapy - General Scoreup to 16 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scoreup to 16 months

Beyond the preview

Go deeper on NCT07714551.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07714551.